Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...
Please provide your email address to receive an email when new articles are posted on . In a phase 3, randomized, double-blind study, researchers compared the safety and efficacy of biosimilar BI ...
On May 20, 2024, Teva Pharmaceuticals (“Teva”) and Alvotech announced the availability of SIMLANDI (adalimumab-ryvk) injection in the United States, for the treatment of adult rheumatoid arthritis, ...
SAN FRANCISCO, U.S. and SUZHOU, China, Sept. 3, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today a ...
Boehringer Ingelheim, which recently launched the first interchangeable biosimilar to AbbVie’s megablockbuster Humira, is getting in on the industry’s double-pricing trick. After debuting its branded ...
Switching to CT-P17 resulted in stable or increased patient satisfaction, especially for those previously on biosimilars or citrate-containing formulations. Patient education and shared ...
REDWOOD CITY, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that YUSIMRY™ (adalimumab-aqvh) is now available for commercial sale in the United States at a ...
Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar ...
Please provide your email address to receive an email when new articles are posted on . Celltrion’s Yuflyma is a high concentration, citrate-free formulation of adalimumab. It is the ninth Humira ...
REDWOOD CITY, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that the company plans to launch YUSIMRY™ (adalimumab-aqvh) in July 2023* with a list price of ...
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its adalimumab injection 9MW0113 (Marketed as Junmaikang in China) has been granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results